• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Strem Brian M. bought $14,997 worth of shares (3,000 units at $5.00), increasing direct ownership by 26% to 14,531 units (SEC Form 4)

    6/13/24 3:49:44 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Strem Brian M.

    (Last) (First) (Middle)
    C/O KIORA PHARMACEUTICALS, INC.
    332 ENCINITAS BLVD., SUITE 102

    (Street)
    ENCINITAS CA 92024

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    KIORA PHARMACEUTICALS INC [ KPRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/13/2024 06/13/2024 P 3,000 A $4.999 14,531 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Melissa Tosca, Attorney-in-Fact 06/13/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KPRX

    DatePrice TargetRatingAnalyst
    1/19/2022$2.50Buy
    Maxim Group
    More analyst ratings

    $KPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

      Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w

      6/15/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

      Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones," said Brian M. Strem, Ph.D., president and CEO of Kiora. "Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonst

      5/9/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting

      Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia and a co-investigator in the study.Patients with Retinitis Pigmentosa (RP)

      5/1/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/12/24 6:32:55 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shapiro Aron bought $10,800 worth of shares (3,000 units at $3.60) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      9/11/24 7:02:13 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walters-Hoffert Lisa bought $4,825 worth of shares (1,250 units at $3.86) (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      8/20/24 1:00:12 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

      Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

      4/21/23 7:00:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

      Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and

      9/13/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board

      Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e

      2/1/22 6:45:00 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    SEC Filings

    See more
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/4/25 2:34:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      6/3/25 7:00:35 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      5/9/25 7:02:08 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Kiora Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50

      1/19/22 8:19:46 AM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Tosca Melissa was granted 7,772 shares, increasing direct ownership by 57% to 21,371 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:29:26 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Daniels Eric Joseph was granted 7,772 shares, increasing direct ownership by 42% to 26,375 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:59 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strem Brian M. was granted 15,941 shares, increasing direct ownership by 53% to 46,103 units (SEC Form 4)

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      4/2/25 8:28:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

      SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 7:17:24 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:45:23 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kiora Pharmaceuticals Inc.

      SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

      11/14/24 4:32:42 PM ET
      $KPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care